Titan Biotech Limited (524717) Fair Value & Analysis

Other · IN · Market cap ₹1.5B

A solid business, screening 42% undervalued on our models.

What matters now

• The rarer combination: high quality (73/100) AND below fair value. That earns a closer look rather than a quick verdict.
• A fairly wide model range (₹276.37 to ₹710.55) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹34.43 – ₹529.20 · fair‑value band ₹276.37 – ₹710.55 · the ₹399.35 price screens below the ₹567.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Titan Biotech Limited (524717) currently trades at ₹399.35, while our model-based Fair Value estimate is ₹567.91, implying the stock looks roughly 42.2% undervalued today. The Quality Score stands at 73/100 (solid quality), in the Other sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Titan Biotech Limited generated revenue of ₹1.1B at a net margin of 21.3%. Revenue grew 76.5% year over year. It earns a return on equity of 49.5%. Net debt stands at ₹21.9M. Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹276.37 (bear case) to ₹710.55 (bull case); at ₹399.35, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 386% above its 52-week low. For context, the median of 10 Other peers we cover trades at -24% fair-value upside, at 42%, 524717 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹767.00) versus Dividend Discount (₹25.58). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Titan Biotech Limited manufactures and sells biological products in India. The company offers food ingredients, including hydrolyzed vegetable protein, yeast extract powder, calcium propionate powder, potassium sorbate, and calcium lactate; collagen and protein products, such as specter whey protein, collagen peptides, brown rice protein, fish collagen, pea …

Full company description

Titan Biotech Limited manufactures and sells biological products in India. The company offers food ingredients, including hydrolyzed vegetable protein, yeast extract powder, calcium propionate powder, potassium sorbate, and calcium lactate; collagen and protein products, such as specter whey protein, collagen peptides, brown rice protein, fish collagen, pea protein isolate, chicken protein isolate, soya protein isolate, milk protein, and protein hydrolysate; and nutraceutical and pharmaceutical products comprising sodium caseinate, chondroitin sulfate, hyaluronic acid, methyl sulphonyl methane, chelated minerals, peptone, OX bile extract, cholic acid, cerebroprotein hydrolysate, methyl sulphonyl methane, iron protein succinylate, medicinal yeast, and brewer yeast protein, as well as liver, meat, malt, and yeast extracts. In addition, it provides products in the areas of animal nutrition, including binding agents, chelates minerals, mold inhibitors, proteins, and yeasts. The company's products are used in the field of pharmaceuticals, nutraceuticals, food and beverages, biotechnology and fermentation, cosmetics, veterinary and animal feed, agriculture, microbiology culture media, plant tissue culture media, etc. The company also exports its products. Titan Biotech Limited was incorporated in 1992 and is based in New Delhi, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Titan Biotech Limited reported revenue of ₹2.1B in FY2026 versus ₹1.2B in FY2022, a compound +13.7%/yr. Reported net income was ₹299M in FY2026, compounding +8.3%/yr from FY2022.

Watch 524717: get an alert when its fair value changes →

Peer Group

Other · 373 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Other median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Other stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.